Coenzyme M
- Generic Name
- Coenzyme M
- Brand Names
- Uromitexan
- Drug Type
- Small Molecule
- Chemical Formula
- C2H6O3S2
- CAS Number
- 3375-50-6
- Unique Ingredient Identifier
- VHD28S0H7F
- Background
Coenzyme M (commonly known by its salt form, Mesna) is a synthetic sulfhydryl (thiol) compound and is used for prophylaxis of Ifosfamide and cyclophosphamide induced hemorrhagic cystitis.
- Indication
Mesna is a uroprotective agent and is used prophylactically to reduce ifosfamide and cyclophosphamide induced hemorrhagic cystitis.
- Associated Conditions
- Hemorrhagic cystitis caused by cyclophosphamide, Hemorrhagic cystitis caused by ifosfamide
- Associated Therapies
- -
Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients
- First Posted Date
- 2011-11-29
- Last Posted Date
- 2021-12-27
- Lead Sponsor
- Polish Lymphoma Research Group
- Target Recruit Count
- 77
- Registration Number
- NCT01481272
- Locations
- 🇵🇱
Instytut Hematologii i Transfuzjologii, Warszawa, Mazowieckie, Poland
🇵🇱Dolnośląskie Centrum Transplantacji Komórkowych, Wrocław, Dolnośląskie, Poland
🇵🇱Uniwersyteckie Cenrum Medyczne, Gdańsk, Pomorskie, Poland
Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial
- Conditions
- Interventions
- First Posted Date
- 2011-10-04
- Last Posted Date
- 2020-07-23
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 44
- Registration Number
- NCT01445821
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
Disrupting the Bone Marrow Microenvironment With G-CSF in Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2011-04-08
- Last Posted Date
- 2016-09-20
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 13
- Registration Number
- NCT01331590
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2011-04-06
- Last Posted Date
- 2020-07-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT01329900
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia
- First Posted Date
- 2011-03-22
- Last Posted Date
- 2022-09-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 31
- Registration Number
- NCT01319981
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Study of Pre-Operative Treatment of Newly-Diagnosed, Surgically-Resectable Osteosarcoma With Doxorubicin, Ifosfamide, Etoposide, and Cisplatin With Early Metabolic Assessment of Response
- First Posted Date
- 2010-12-13
- Last Posted Date
- 2013-12-10
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 2
- Registration Number
- NCT01258634
- Locations
- 🇺🇸
University of Chicago Department of Pediatrics Hematology/Oncology, Chicago, Illinois, United States
Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release
- Conditions
- Interventions
- First Posted Date
- 2010-09-20
- Last Posted Date
- 2016-02-24
- Lead Sponsor
- Mara Chambers
- Target Recruit Count
- 32
- Registration Number
- NCT01205503
- Locations
- 🇺🇸
University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States
Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2010-07-26
- Last Posted Date
- 2021-01-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 62
- Registration Number
- NCT01169636
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma
- Conditions
- Interventions
- First Posted Date
- 2010-03-31
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 479
- Registration Number
- NCT01096368
- Locations
- 🇨🇦
Hospital for Sick Children, Toronto, Ontario, Canada
🇺🇸University of Illinois, Chicago, Illinois, United States
🇺🇸Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide
- First Posted Date
- 2009-11-09
- Last Posted Date
- 2020-03-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 176
- Registration Number
- NCT01010217
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.